Lymphoma. Hodgkinlymfomen and non-Hodgkin's disease
Information on current developments in both regular and alternative or complementary treatments and resources for lymphoma - non-Hodgkin's lymphoma and Hodgkin's disease at all stages.
Recent articles in left column more or less in alphabetical order classified
Experiences of cancer patients with complementary approaches can be found by experience stories on our website and there are also some videos of experiences of cancer patients with complementary approaches to see. To click on video button top left of this page. Or visit the website of the SNFK information where movies are shown on complementary approaches to cancer.
Irradiation-Radio therapy in non-Hodgkin's lymphoma stage III and IV low-grade gives remarkable longer period to relapse and significantly more total remissions (CR 60% average 42 months long), in spite of one or more chemotherapy that has already been done, thus randomized phase III study in multiple hospitals in Netherlands and Belgium.
This article is a few hours worked. Lookup, translate, places etc. If you want to support us you can do so through a donation anonymous or not. Any amount is welcome no matter how small. Click here if you want to help us to keep cancer-news online We are an ANBI organization and so your donation is tax-deductible.
11 January 2012:
Interesting to mention is in addition to the information below from 2010 a review article of the approach with radio therapy-irradiation in combination with shapes of chemo and immuuntherapeutische resources including Zevalin and Bexxar and Yttrium-90: Radioimmunotherapy or Non-Disease Lymphoma: From the ' Magic Bullets ' to ' Radioactive Magic Bullets '
In the abstract state this, but click on this link for the full study report. Down state information about radio immunotherapies in Belgium:
Source: Radioimmunotherapy (RIT) or lymphoma with Zevalin and Bexxar was approved by FDA in 2002 and 2003, respectively, for the treatment of relapsed or refractory follicular CD20 + B-cell non-Hodgkin's lymphoma ´ s. In 2009, Zevalin was also approved for consolidation therapy in patients with follicular non-Disease lymphoma that achieve a partial or complete response to first-line chemotherapy. For follicular lymphoma patients, the overall response and progression-free survival rates have significantly improved since the implementation or ride. The predominant hematological toxicity complication or ride is that is usually manageable. There are ongoing trials to further define the expanding role of RIDE as first line or concomitant therapy in the treatment of lymphoma as well as for certain antibiotic resistant infections and aggressive malignancies. There is also growing interest in the development of newer protocols for increased and more uniform dose delivery resulting in better outcomes and improved patient survival. This review will primarily focus on the role or RIDE in treatment of non-Disease lymphoma, which is established or clinical utility and FDA approved. The mechanism of RIDE, available radionuclides and pharmacokinetics, therapy administration, clinical utility and toxicities, and future directions would be discussed.
30 May 2005: Source: thanks to Maurice who noticed this message about us study conducted in the Dr. Bernhard Verbeeten Institute
Local radio therapy-radiotherapy for low-grade Non-Hodgkin's lymphoma and stage III and IV would according to a publication of the study a remarkably larger number of total remissions-62%-achieve a low grade non-Hodgkin patients with stage III and IV in spite of the fact that it already one or sometimes several chemotherapy had gotten. In a number of hospitals in Belgium and Netherlands and then in the Dr. Bernhard Verbeeten Institute in Tilburg, let hyperthermia is also in this Institute and given much attention is given to certain additional targeted nutrition in an otherwise regular Institute specialized in radiotherapy and nuclear medicine (internal irradiation e.g. is also done) are last years from 1995 to 2005 hundreds of patients with low-grade non-Hodgkin's stage III and IV extra irradiated locally. Of the group treated patients responded 92% positive on this treatment and remained in remission and that also came 62% average 42 months in the irradiated area. The other 30% received a partial remission on average ten months loved to a subsequent relapse. It will be interesting to know whether this group of patients also the additional power supply is included in the results and whether there is also to meet and whether there is in addition to the irradiation given hyperthermia. but the study published June 2005 we have understood. Be nice that we now all these pre-information notice for you through Maurice have available, once the study is published, we hope also the abstract or perhaps also the full study available for you to get. OPS-members for we have contact and address information of doctors/scientists who performed this study Commission available and you can also specify new follow-up study with this approach, whereby the results of the standard treatment, consisting of six cures chlorambucil, compared with two irradiations of each two Gray on the demonstrated abnormalities.
Radio therapy brings more often and longer total remission Soon appear in the Journal of Clinical Oncology the results of a study which limited the effectiveness of radiotherapy in the treatment of the stage three and four low-grade Non-Hodgkin's lymphoma describes. Radio therapy as treatment method found to be very effective.
The Dr. Bernard Verbeeten Institute is one of the institutions who participated in the study. Radio therapist-oncologist Philip Port mans is one of the writers of the said article. "One of theproblems with chemotherapy for this condition is that, if the tumor and return there again a chemotherapy is given, the duration of the activity still declining further. After the first series the tumor on average two years away, cures continues after the second approximately fifteen months and so are the intervals have a number of months smaller. " In the case can be only treated locally seems limited local radiotherapy with 4 Gray in one or two irradiation groups a more obvious option. In the study, which ran from 1995 and for which the BVI has made a large number of patients, showed that 92 percent of the patients well on local radio therapy stops. Of them has a 62% complete remission which average 42 months within irradiated area. At the other 30 percent is a partial remission with an average duration of ten months. These results are achieved, regardless of whether the patient in an earlier stage has undergone one or more chemotherapy. In a new prospective study in patients with stage 3 or 4 low-grade Non-Hodgkin's lymphoma the results of the standard treatment, consisting of six cures chlorambucil, compared with two irradiations of each two Gray on the demonstrated abnormalities. To this study, which is led by the HOVON with cooperation of the EORTC Lymphoma Group, in our region multiple hospitals and Dr. Bernard Verbeeten Institute part.
